## Contents

List of Statistical Notations: Commonly Used Names and Symbols х Foreword, by A. JOHN RUSH xi Preface xv Acknowledgments xxi 1. Introduction 1 5 2. Disorder and Diagnosis The Disorder 5 The Diagnosis of the Disorder 6 Diagnostic and Prognostic Tests 8 The Basic Model 9 The Prevalence and Reproducibility of the Diagnosis 14 High- and Low-Risk Populations 15 Pre- and Posttest Risk, Prevalence, and Incidence: Confusing Terms 16 Summary 17 3. Definition: Test Protocol, Response, Referent 18 The Basic Model 20 Summary 21 4. Families of Test Referents 23 Definitions: Base and Family 23 A Special Family: Multiple Discriminant Rules 25 Summary 25

5. Population and Sampling 26 Outcomes: True and False Positives and Negatives 26 Blind Evaluation 28 The Basic Model 29 Descriptors of Outcomes: Sensitivity, Specificity, Predictive Values, and Efficiency 33 Naturalistic Sampling 34 The Two-by-Two Chi-Square Test 40 Retrospective Sampling 44 The Problem of Dropouts 49 Prospective Sampling 53 The Sampling Unit 57 Pseudo-Retrospective Sampling: An Invalid Approach 58 Summary 61 6. Sensitivity and Specificity: The Signal Detection Approach 63 Problems with Sensitivity and Specificity 63 The Basic Model 65 The Receiver Operating Characteristic Curve (Test ROC) 71 The Quality Receiver Operating Characteristic Curve (QROC) 75 All Q-Level Tests 77 What Is a Good Test? The Diagnosis ROC, QROC 82 What Is the Ideal Test? The Disorder ROC, QROC 86 The Myth of the Constancy of Sensitivity and Specificity 91 Summary 94 7. Predictive Values: The Bayesian Approach, Risk Ratios, and Odds Ratio 96 Problems with Predictive Values 96 The Basic Model 98 A Geometric Approach: The Test QROC 100 Risk Ratios, Odds Ratio, and the Test QROC 103 Summary 113 8. Efficiency: Choosing Clinically Optimal Tests 114 The Problem with Efficiency 114 The Basic Model 115 Consideration of Medical Consequences of Errors: The Weighted Kappa Coefficient 119 A Geometric Approach: The Test QROC 123 Summary 129 9. Taking Test Costs into Account: Costworthy Tests 131 Introduction 131 The Basic Model 135

Derivation of the Quality Index  $\kappa(r,t)$  135

The Benefit Threshold of a Medical Test 138 Full Evaluation of a Test Family 140 A Geometric Approach: The QCROC 145 149 The Costs and Risks of Too Much Information Informed Consent for Medical Tests 151 Summary 153 155 10. Basic Issues in Using Multiple Tests Introduction 155 Tests in Parallel or Tests in Sequence 156 The Quality of Combined Tests 161 When Should a Test Be Repeated? 163 Should a Test Be Done Blind to Previous Test Results? 163 Summary 164 165 11. Evaluating Batteries of Medical Tests: Optimal Sequences Introduction 165 The Basic Model 166 Compiling the Raw Data Base 170 Compiling the Working Data Base 176 Selection of the Optimal First Test and Reiteration 179 Increasing the Yield 180Testing the Quality Index Using a Statistical Jackknife 185 Completing the Search for the Optimal Battery Structure 187 The Final Recommendation for Battery Structure 188An Alternative Strategy 193 Summary 194 12. Evaluating Batteries of Medical Tests: Optimal Scores 199 Introduction 199 The Basic Model 204Multiple Linear Discrimination 209 Logistic Regression Analysis 216 Some Practical Considerations in Choosing and Using Models 222 Summary 227 Evaluating Batteries of Prognostic Tests with Variable Follow-Up Times 228 228 Introduction 231 The Basic Model 234 Ignoring the Problem of Variable Follow-Up: A Possibly Invalid Approach 234 *Counting Time and Not Patients: Another Possibly Invalid Procedure* Tailoring the Data to Fit the Solution: An Invalid and Inefficient Approach 239 Estimating Survival Curves with Variable Follow-Up Times: The Kaplan-Meier Method 241

Some General Observations on the Choice of Follow-Up Time and Its
Evaluating a Family of Prognostic Tests with a Variable Follow-Un Time 250
An Alternative? Randomized Clinical Trials for the Evaluation of
Screening Programs (Test + Intergention) for Prevention 256
Final vating a Battery of Prognostic Tests with Variable Follow-1 In
Periode: Sequential Structuring 259
Fulluating a Battery of Prognostic Tests Using Variable Follow-Un
Scoring a Battery with the Proportional Hazards Model 259
Summary 263
14 Evaluation of Medical Tests: The Past Present and Future 266
Introduction: The Past and the Present 266
The Future: I Insolved Problems 272
Problem: Evaluation of Monitoring Tests 272
Problem: Multicategory Responses 273
Problem: Stoming Rules 274
Other Problems 275
The Present: An Overall Summary 276
What Is the Disorder? What Diagnosis Is to Be Used? Is the
Diagnosis Clinically Valid and Reliable? 276
In What Clinical Population or Populations Is the Test Proposed for
Use? How Can the Sampling Be Done so as to Obtain a
Representative Sample from That Population or Populations? 277
If the Test Is to Be Evaluated as a Prognostic Test, Will the
Follow-Up Be Fixed or Variable? If the Follow-Up Is to Be Fixed,
Fixed at What Time? 277
Will Sampling Be Naturalistic, Retrospective, or Prospective? 277
How Large a Sample Is Needed? 278
How Are Dropouts and Missing Responses Avoided? 278
What Are the Clinical Benefits in this Situation? 279
What Are the Tests Under Evaluation—Their Protocols, Responses,
and Referents? What Are the Test Costs? If This is a Single Test
(a Single Fixed Cost for All the Responses) or Is This to Be
Considered a Battery of Tests (Separable Costs)? 279
How Are the Blinding of the Diagnosis and Test Results Assured? If
There Are Multiple Tests in a Battery Under Evaluation, Are
These Blinded to Each Other? 280
Is There any Internal or External Standard Provided for the
Performance of an Excellent Test? 280
vvas the Data Base Properly Compiled and Thoroughly Checked for Errors? 281
For Each Single Test Under Evaluation, for Each Test in the Battery
Under Evaluation, and for Each Population Under Evaluation,
Have the Descriptive Statistics Been Properly Computed? 282

 What Is the Quality of Each Single Test Under Evaluation, and for Each Population Under Evaluation (and in an Evaluation of a Prognostic Test with Variable Follow-Up Time, for Each Possible Value of Follow-Up Time)? 282

Has the Optimal Referent for a Test, or the Optimal First Test in a Battery of Tests Been Appropriately Selected? 284

If There Is a Battery of Tests Under Consideration, Has the Battery Been Appropriately Evaluated? 285

References 286

Index 291

About the Author 295